Nanotechnology applied to overcome tumor drug resistance

Journal of Controlled Release

Volumn 162, Issue 1, 2012, Pages 45-55

  Gao, Zibin ^a   Zhang, Linan ^a   Sun, Yongjun ^a  

^a HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemotherapy; Drug delivery system; Emerging multidrug resistance; Nanotechnology; Tumor

Indexed keywords

ANTICANCER DRUG; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; MALIGNANT DISEASE; MULTIDRUG RESISTANCE; NANOCARRIERS; OPTIMAL DOSAGE; SMALL MOLECULES; TRANSPORT KINETIC; TUMOR CELLS; TUMOR MICROENVIRONMENT; TUMOR-STROMA;

CHEMOTHERAPY; DRUG DELIVERY; DRUG PRODUCTS; TUMORS;

NANOTECHNOLOGY;

ANTINEOPLASTIC AGENT; BIRICODAR; CYCLOSPORIN A; DEQUALINIUM; DOXORUBICIN; LAPATINIB; PACLITAXEL; POLYMER; SINGLE WALLED NANOTUBE; SMALL INTERFERING RNA; TARIQUIDAR; VALSPODAR; VERAPAMIL;

BREAST CANCER; CANCER RESISTANCE; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENERGY METABOLISM; GENE SILENCING; GENE TARGETING; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84864696659     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.05.051     Document Type: Review

References (134)

1. B. Desoize, and J. Jardillier Multicellular resistance: a paradigm for clinical resistance? Crit. Rev. Oncol. Hematol. 36 2000 193 207
2. Y.A. Luqmani Mechanisms of drug resistance in cancer chemotherapy Med. Princ. Pract. 14 Suppl. 1 2005 35 48
3. A.L. Harris, and D. Hochhauser Mechanisms of multidrug resistance in cancer treatment Acta Oncol. 31 1992 205 213
4. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
5. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
6. B.C. Baguley Multidrug resistance in cancer Methods Mol. Biol. 596 2010 1 14
7. R.I. Pakunlu, Y. Wang, W. Tsao, V. Pozharov, T.J. Cook, and T. Minko Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system Cancer Res. 64 2004 6214 6224
8. M. Saad, O.B. Garbuzenko, and T. Minko Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine (Lond.) 3 2008 761 776
9. L. Milane, Z.F. Duan, and M. Amiji Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded. EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer Nanomedicine 7 2011 435 444
10. Y. Patil, T. Sadhukha, L. Ma, and J. Panyam Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance J. Control. Release 136 2009 21 29
11. X.B. Xiong, Z. Ma, R. Lai, and A. Lavasanifar The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin Biomaterials 31 2010 757 768
12. Y. Zhou, L. Shi, Q. Li, H. Jiang, G. Lv, J. Zhao, C. Wu, M. Selke, and X. Wang Imaging and inhibition of multi-drug resistance in cancer cells via specific association with negatively charged CdTe quantum dots Biomaterials 31 2010 4958 4963
13. Y.J. Gu, J. Cheng, C.W. Man, W.T. Wong, and S.H. Cheng Gold-doxorubicin nanoconjugates for overcoming multidrug resistance Nanomedicine 8 2012 204 211
14. S. Kunjachan, A. Blauz, D. Mockel, B. Theek, F. Kiessling, T. Etrych, K. Ulbrich, L.V. Bloois, G. Storm, G. Bartosz, B. Rychlik, and T. Lammers Overcoming cellular multidrug resistance using classical nanomedicine formulations Eur. J. Pharm. Sci. 45 2012 421 428
15. M. Studenovsky, K. Ulbrich, M. Ibrahimova, and B. Rihova Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin Eur. J. Pharm. Sci. 42 2011 156 163
16. K. Kono, C. Kojima, N. Hayashi, E. Nishisaka, K. Kiura, S. Watarai, and A. Harada Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin Biomaterials 29 2008 1664 1675
17. J.A. MacDiarmid, and H. Brahmbhatt Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy Curr. Opin. Biotechnol. 22 2011 909 916
18. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
19. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U. S. A. 95 1998 4607 4612
20. D.R. Siwak, A.M. Tari, and G. Lopez-Berestein The potential of drug-carrying immunoliposomes as anticancer agents (Commentary re:) J.W. Park, Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery Clin. Cancer Res. 8 2002 1172 1181 Clin. Cancer Res. 8 2002 955 956
21. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 2000 1363 1380
22. M. Zhao, M. Yang, X.M. Li, P. Jiang, E. Baranov, S. Li, M. Xu, S. Penman, and R.M. Hoffman Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium Proc. Natl. Acad. Sci. U. S. A. 102 2005 755 760
23. R.M. Hoffman Tumor-targeting amino acid auxotrophic Salmonella typhimurium Amino Acids 37 2009 509 521
24. H.S. Choi, W. Liu, F. Liu, K. Nasr, P. Misra, M.G. Bawendi, and J.V. Frangioni Design considerations for tumour-targeted nanoparticles Nat. Nanotechnol. 5 2010 42 47
25. A.K. Gupta, and M. Gupta Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications Biomaterials 26 2005 3995 4021
26. E.S. Lee, K. Na, and Y.H. Bae Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor J Control. Release 103 2005 405 418
27. Y.L. Lin, Y.K. Liu, N.M. Tsai, J.H. Hsieh, C.H. Chen, C.M. Lin, and K.W. Liao A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells Nanomedicine 8 2012 318 327
28. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
29. C.J. Li, Y. Miyamoto, Y. Kojima, and H. Maeda Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure Br. J. Cancer 67 1993 975 980
30. A. Nagamitsu, T. Inuzuka, K. Greish, and H. Maeda SMANCS dynamic therapy for various advanced solid tumors and promising clinical effects: enhanced drug delivery by hydrodynamic modulation with vascular mediators, particularly angiotensin II, during arterial infusion Drug Deliv. Syst. 22-5 2007 510 521
31. W.L. Monsky, D. Fukumura, T. Gohongi, M. Ancukiewcz, H.A. Weich, V.P. Torchilin, F. Yuan, and R.K. Jain Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor Cancer Res. 59 1999 4129 4135
32. D. Bazile, C. Prud'homme, M.T. Bassoullet, M. Marlard, G. Spenlehauer, and M. Veillard Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system J. Pharm. Sci. 84 1995 493 498
33. A. Gabizon, and D. Papahadjopoulos Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. U. S. A. 85 1988 6949 6953
34. M. Hamidi, P. Rafiei, and A. Azadi Designing PEGylated therapeutic molecules: advantages in ADMET properties Expert Opin. Drug Discov. 3 2008 1293 1307
35. D.E. Owens 3rd, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
36. D. Bhadra, S. Bhadra, P. Jain, and N.K. Jain Pegnology: a review of PEG-ylated systems Pharmazie 57 2002 5 29
37. J.C. Olivier Drug transport to brain with targeted nanoparticles NeuroRx 2 2005 108 119
38. M. Hamidi, A. Azadi, and P. Rafiei Hydrogel nanoparticles in drug delivery Adv. Drug Deliv. Rev. 60 2008 1638 1649
39. S.D. Li, and L. Huang Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells Mol. Pharm. 3 2006 579 588
40. C.M. Galmarini, G. Warren, M.T. Senanayake, and S.V. Vinogradov Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs Int. J. Pharm. 395 2010 281 289
41. J. Jiang, S.J. Yang, J.C. Wang, L.J. Yang, Z.Z. Xu, T. Yang, X.Y. Liu, and Q. Zhang Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin Eur. J. Pharm. Biopharm. 76 2010 170 178
42. J.A. Boomer, M.M. Qualls, H.D. Inerowicz, R.H. Haynes, V.S. Patri, J.M. Kim, and D.H. Thompson Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate Bioconjug. Chem. 20 2009 47 59
43. H. Xu, K.Q. Wang, Y.H. Deng, and W. Chen da Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes Biomaterials 31 2010 4757 4763
44. E.S. Lee, Z. Gao, D. Kim, K. Park, I.C. Kwon, and Y.H. Bae Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance J. Control. Release 129 2008 228 236
45. J.G. Huang, T. Leshuk, and F.X. Gu Emerging nanomaterials for targeting subcellular organelles Nano Today 6 2011 478 492
46. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
47. F. Shen, S. Chu, A.K. Bence, B. Bailey, X. Xue, P.A. Erickson, M.H. Montrose, W.T. Beck, and L.C. Erickson Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells J. Pharmacol. Exp. Ther. 324 2008 95 102
48. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
49. N. Dinauer, S. Balthasar, C. Weber, J. Kreuter, K. Langer, and H. von Briesen Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes Biomaterials 26 2005 5898 5906
50. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
51. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
52. M.G. Qaddoumi, H. Ueda, J. Yang, J. Davda, V. Labhasetwar, and V.H. Lee The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers Pharm. Res. 21 2004 641 648
53. J. Panyam, S.K. Sahoo, S. Prabha, T. Bargar, and V. Labhasetwar Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d, l-lactide-co-glycolide) nanoparticles Int. J. Pharm. 262 2003 1 11
54. A.M. Wu, P.J. Yazaki, S. Tsai, K. Nguyen, A.L. Anderson, D.W. McCarthy, M.J. Welch, J.E. Shively, L.E. Williams, A.A. Raubitschek, J.Y. Wong, T. Toyokuni, M.E. Phelps, and S.S. Gambhir High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment Proc. Natl. Acad. Sci. U. S. A. 97 2000 8495 8500
55. J. Zhao, C.S. Liu, Y. Yuan, X.Y. Tao, X.Q. Shan, Y. Sheng, and F. Wu Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers Biomaterials 28 2007 1414 1422
56. N. Debotton, M. Parnes, J. Kadouche, and S. Benita Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles J. Control. Release 127 2008 219 230
57. K.F. Pirollo, and E.H. Chang Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 26 2008 552 558
58. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701
59. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahadjopoulos, and R.K. Jain Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 54 1994 3352 3356
60. Z. Xu, Z. Zhang, Y. Chen, L. Chen, L. Lin, and Y. Li The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model Biomaterials 31 2010 916 922
61. J.A. MacDiarmid, N.B. Amaro-Mugridge, J. Madrid-Weiss, I. Sedliarou, S. Wetzel, K. Kochar, V.N. Brahmbhatt, L. Phillips, S.T. Pattison, C. Petti, B. Stillman, R.M. Graham, and H. Brahmbhatt Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug Nat. Biotechnol. 27 2009 643 651
62. Y.B. Patil, S.K. Swaminathan, T. Sadhukha, L. Ma, and J. Panyam The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance Biomaterials 31 2010 358 365
63. J. Wang, X. Tao, Y. Zhang, D. Wei, and Y. Ren Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles Biomaterials 31 2010 4426 4433
64. J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, and R.J. Lee Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil J. Pharm. Pharm. Sci. 10 2007 350 357
65. R. Li, R. Wu, L. Zhao, M. Wu, L. Yang, and H. Zou P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells ACS Nano 4 2010 1399 1408
66. D.J. Yamashiro, and F.R. Maxfield Regulation of endocytic processes by pH Trends Pharmacol. Sci. 9 1988 190 193
67. S. Yadav, L.E. van Vlerken, S.R. Little, and M.M. Amiji Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells Cancer Chemother. Pharmacol. 63 2009 711 722
68. F.M. Kievit, F.Y. Wang, C. Fang, H. Mok, K. Wang, J.R. Silber, R.G. Ellenbogen, and M. Zhang Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro J. Control. Release 152 2011 76 83
69. L. Jabr-Milane, L. van Vlerken, H. Devalapally, D. Shenoy, S. Komareddy, M. Bhavsar, and M. Amiji Multi-functional nanocarriers for targeted delivery of drugs and genes J. Control. Release 130 2008 121 128
70. K. Engin, D.B. Leeper, J.R. Cater, A.J. Thistlethwaite, L. Tupchong, and J.D. McFarlane Extracellular pH distribution in human tumours Int. J. Hyperthermia 11 1995 211 216
71. R. Chen, S. Khormaee, M.E. Eccleston, and N.K. Slater The role of hydrophobic amino acid grafts in the enhancement of membrane-disruptive activity of pH-responsive pseudo-peptides Biomaterials 30 2009 1954 1961
72. A.K. Larsen, A.E. Escargueil, and A. Skladanowski Resistance mechanisms associated with altered intracellular distribution of anticancer agents Pharmacol. Ther. 85 2000 217 229
73. Y. Shen, H. Tang, Y. Zhan, E.A. Van Kirk, and W.J. Murdoch Degradable poly(beta-amino ester) nanoparticles for cancer cytoplasmic drug delivery Nanomedicine 5 2009 192 201
74. C.H. Wang, S.H. Chiou, C.P. Chou, Y.C. Chen, Y.J. Huang, and C.A. Peng Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody Nanomedicine 7 2011 69 79
75. C. Fan, W. Gao, Z. Chen, H. Fan, M. Li, F. Deng, and Z. Chen Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles Int. J. Pharm. 404 2011 180 190
76. J. Chen, D. Wang, J. Xi, L. Au, A. Siekkinen, A. Warsen, Z.Y. Li, H. Zhang, Y. Xia, and X. Li Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells Nano Lett. 7 2007 1318 1322
77. M.Y. Hua, H.W. Yang, H.L. Liu, R.Y. Tsai, S.T. Pang, K.L. Chuang, Y.S. Chang, T.L. Hwang, Y.H. Chang, H.C. Chuang, and C.K. Chuang Superhigh- magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy Biomaterials 32 2011 8999 9010
78. H.L. Lu, W.J. Syu, N. Nishiyama, K. Kataoka, and P.S. Lai Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo J. Control. Release 155 2011 458 464
79. S. Febvay, D.M. Marini, A.M. Belcher, and D.E. Clapham Targeted cytosolic delivery of cell-impermeable compounds by nanoparticle-mediated, light-triggered endosome disruption Nano Lett. 10 2010 2211 2219
80. D. Guo, C. Wu, H. Jiang, Q. Li, X. Wang, and B. Chen Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation J. Photochem. Photobiol. B 93 2008 119 126
81. E.Y. Lukianova-Hleb, A. Belyanin, S. Kashinath, X. Wu, and D.O. Lapotko Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells Biomaterials 33 2012 1821 1826
82. M.J. Shieh, C.Y. Hsu, L.Y. Huang, H.Y. Chen, F.H. Huang, and P.S. Lai Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells J. Control. Release 152 2011 418 425
83. N. Rapoport Combined cancer therapy by micellar-encapsulated drug and ultrasound Int. J. Pharm. 277 2004 155 162
84. Y. Liu, K. Lillehei, W.N. Cobb, U. Christians, and K.Y. Ng Overcoming MDR by ultrasound-induced hyperthermia and P-glycoprotein modulation Biochem. Biophys. Res. Commun. 289 2001 62 68
85. A. Marin, H. Sun, G.A. Husseini, W.G. Pitt, D.A. Christensen, and N.Y. Rapoport Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake J. Control. Release 84 2002 39 47
86. U. Kedar, P. Phutane, S. Shidhaye, and V. Kadam Advances in polymeric micelles for drug delivery and tumor targeting Nanomedicine 6 2010 714 729
87. B. Howard, Z. Gao, and S.W. Lee Ultrasound-enhanced chemotherapy of drug-resistant breast cancer tumors by micellar-encapsulated paclitaxel Am. J. Drug Deliv. 4 2006 97 104
88. L. Milane, S. Ganesh, S. Shah, Z.F. Duan, and M. Amiji Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology J. Control. Release 155 2011 237 247
89. E. Teodori, S. Dei, S. Scapecchi, and F. Gualtieri The medicinal chemistry of multidrug resistance (MDR) reversing drugs Farmaco 57 2002 385 415
90. M. Hubensack, C. Muller, P. Hocherl, S. Fellner, T. Spruss, G. Bernhardt, and A. Buschauer Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice J. Cancer Res. Clin. Oncol. 134 2008 597 607
91. M. Bebawy, and D.M. Sze Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics Curr. Cancer Drug Targets 8 2008 47 52
92. K. Linnet, and T.B. Ejsing A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs Eur. Neuropsychopharmacol. 18 2008 157 169
93. L. van Zuylen, J. Verweij, K. Nooter, E. Brouwer, G. Stoter, and A. Sparreboom Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans Clin. Cancer Res. 6 2000 2598 2603
94. X.R. Song, Z. Cai, Y. Zheng, G. He, F.Y. Cui, D.Q. Gong, S.X. Hou, S.J. Xiong, X.J. Lei, and Y.Q. Wei Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles Eur. J. Pharm. Sci. 37 2009 300 305
95. H. Devalapally, Z. Duan, M.V. Seiden, and M.M. Amiji Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 2008 3193 3203
96. H.J. Cho, H.Y. Yoon, H. Koo, S.H. Ko, J.S. Shim, J.H. Lee, K. Kim, I.C. Kwon, and D.D. Kim Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic(R) for tumor-targeted delivery of docetaxel Biomaterials 32 2011 7181 7190
97. Q. He, Y. Gao, L. Zhang, Z. Zhang, F. Gao, X. Ji, Y. Li, and J. Shi A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance Biomaterials 32 2011 7711 7720
98. D. Vergara, C. Bellomo, X. Zhang, V. Vergaro, A. Tinelli, V. Lorusso, R. Rinaldi, Y.M. Lvov, S. Leporatti, and M. Maffia Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer Nanomedicine 2011 (http://www.ncbi.nlm.nih.gov/pubmed/22100754)
99. C. Liu, G. Zhao, J. Liu, N. Ma, P. Chivukula, L. Perelman, K. Okada, Z. Chen, D. Gough, and L. Yu Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel J. Control. Release 140 2009 277 283
100. R.I. Pakunlu, Y. Wang, M. Saad, J.J. Khandare, V. Starovoytov, and T. Minko In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug J. Control. Release 114 2006 153 162
101. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J.I. Zink, and A.E. Nel Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line ACS Nano 4 2010 4539 4550
102. Y. Yu, Z.H. Wang, L. Zhang, H.J. Yao, Y. Zhang, R.J. Li, R.J. Ju, X.X. Wang, J. Zhou, N. Li, and W.L. Lu Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma Biomaterials 33 2012 1808 1820
103. X.X. Wang, Y.B. Li, H.J. Yao, R.J. Ju, Y. Zhang, R.J. Li, Y. Yu, L. Zhang, and W.L. Lu The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells Biomaterials 32 2011 5673 5687
104. E.V. Batrakova, and A.V. Kabanov Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers J. Control. Release 130 2008 98 106
105. E.V. Batrakova, S. Li, A.M. Brynskikh, A.K. Sharma, Y. Li, M. Boska, N. Gong, R.L. Mosley, V.Y. Alakhov, H.E. Gendelman, and A.V. Kabanov Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers J. Control. Release 143 2010 290 301
106. Y. Zhang, L. Tang, L. Sun, J. Bao, C. Song, L. Huang, K. Liu, Y. Tian, G. Tian, Z. Li, H. Sun, and L. Mei A novel paclitaxel-loaded poly(epsilon- caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment Acta Biomater. 6 2010 2045 2052
107. X. Ji, Y. Gao, L. Chen, Z. Zhang, Y. Deng, and Y. Li Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance Int. J. Pharm. 422 2012 390 397
108. W. Zhang, Y. Shi, Y. Chen, J. Ye, X. Sha, and X. Fang Multifunctional pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors Biomaterials 32 2011 2894 2906
109. Q. He, J. Shi, F. Chen, M. Zhu, and L. Zhang An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles Biomaterials 31 2010 3335 3346
110. H. Riehm, and J.L. Biedler Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin Cancer Res. 32 1972 1195 1200
111. D.W. Loe, and F.J. Sharom Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles Br. J. Cancer 68 1993 342 351
112. J. Kopecek, and H. Bazilova Poly[N-(2-hydroxypropyl)methacrylamide]. I. Radical polymerization and copolymerization Eur. Polym. 9 1973 7 14
113. L. Sprincl, J. Exner, O. Sterba, and J. Kopecek New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl) methacrylamide] in a test organism J. Biomed. Mater. Res. 10 1976 953 963
114. E. Segal, H. Pan, L. Benayoun, P. Kopeckova, Y. Shaked, J. Kopecek, and R. Satchi-Fainaro Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances Biomaterials 32 2011 4450 4463
115. T. Etrycha, H. Krakovičováa, M. Šírová b, B. Říhováb, and K. Ulbrich HPMAcopolymerconjugates for dualtherapy J. Control. Release 132 2008 e63 e65
116. J. Hongrapipat, P. Kopeckova, S. Prakongpan, and J. Kopecek Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs Int. J. Pharm. 351 2008 259 270
117. K. Greish, A. Ray, H. Bauer, N. Larson, A. Malugin, D. Pike, M. Haider, and H. Ghandehari Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy J. Control. Release 151 2011 263 270
118. Q. Xiang, Y. Yang, Z. Zhou, D. Zhou, Y. Jin, Z. Zhang, and Y. Huang Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells Eur. J. Pharm. Biopharm. 80 2012 379 386
119. Y. Yang, Z. Zhou, S. He, T. Fan, Y. Jin, X. Zhu, C. Chen, Z.R. Zhang, and Y. Huang Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates Biomaterials 33 2012 2260 2271
120. M.P. Borgman, T. Coleman, R.B. Kolhatkar, S. Geyser-Stoops, B.R. Line, and H. Ghandehari Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation J. Control. Release 132 2008 193 199
121. A. Mitra, J. Mulholland, A. Nan, E. McNeill, H. Ghandehari, and B.R. Line Targeting tumor angiogenic vasculature using polymer-RGD conjugates J. Control. Release 102 2005 191 201
122. P.J. Julyan, L.W. Seymour, D.R. Ferry, S. Daryani, C.M. Boivin, J. Doran, M. David, D. Anderson, C. Christodoulou, A.M. Young, S. Hesslewood, and D.J. Kerr Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine J. Control. Release 57 1999 281 290
123. R.N. Johnson, D.S. Chu, J. Shi, J.G. Schellinger, P.M. Carlson, and S.H. Pun HPMA-oligolysine copolymers for gene delivery: optimization of peptide length and polymer molecular weight J. Control. Release 155 2011 303 311
124. Z. Qin, W. Liu, L. Guo, and X. Li Preparation and characterization of guanidinated N-3-aminopropyl methacrylamide-N-2-hydroxypropyl methacrylamide copolymers as gene delivery carriers J. Control. Release 152 Suppl. 1 2011 e168 e170
125. J. Shi, R.N. Johnson, J.G. Schellinger, P.M. Carlson, and S.H. Pun Reducible HPMA-co-oligolysine copolymers for nucleic acid delivery Int. J. Pharm. 427 2012 113 122
126. T. Etrych, T. Mrkvan, B. Rihova, and K. Ulbrich Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy J. Control. Release 122 2007 31 38
127. R. Duncan Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt Adv. Drug Deliv. Rev. 61 2009 1131 1148
128. P.C. Griffiths, A. Paul, B. Apostolovic, H.A. Klok, E. de Luca, S.M. King, and R.K. Heenan Conformational consequences of cooperative binding of a coiled-coil peptide motif to poly(N-(2-hydroxypropyl) methacrylamide) HPMA copolymers J. Control. Release 153 2011 173 179
129. S. Zalipsky, M. Saad, R. Kiwan, E. Ber, N. Yu, and T. Minko Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action J. Drug Target 15 2007 518 530
130. T. Minko, P. Kopeckova, V. Pozharov, and J. Kopecek HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line J. Control. Release 54 1998 223 233
131. T. Minko, P. Kopeckova, and J. Kopecek Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line J. Control. Release 59 1999 133 148
132. M. Tijerina, K.D. Fowers, P. Kopeckova, and J. Kopecek Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance Biomaterials 21 2000 2203 2210
133. T. Minko, P. Kopeckova, and J. Kopecek Preliminary evaluation of caspasesdependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells J. Control. Release 71 2001 227 237
134. T. Minko HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance Adv. Drug Deliv. Rev. 62 2010 192 202